A carregar...
Pathological complete response to neoadjuvant trastuzumab and pertuzumab therapy is related to human epidermal growth factor receptor 2 (HER2) amplification level in HER2-amplified breast cancer
The human epidermal growth factor receptor 2 (HER2) is amplified in approximately 20% of breast cancers, and HER2 receptor targeting therapy is associated with a significant improvement in disease-free and overall survival. In several clinical trials, the pathologic complete response (pCR) rate was...
Na minha lista:
| Publicado no: | Medicine (Baltimore) |
|---|---|
| Main Authors: | , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Lippincott Williams & Wilkins
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7668516/ https://ncbi.nlm.nih.gov/pubmed/33181670 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/MD.0000000000023053 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|